ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,304Medicare Part D Prescriptions Filled, Including Refills

Rank: 356 out of 2888

$538K Total Retail Price of All Prescriptions

Rank: 749 out of 2888

479 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 479 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 11,453 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$44 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
SIMVASTATIN 866 797 1 2
LISINOPRIL 723 687 2 3
AMLODIPINE BESYLATE 654 622 3 5
ATORVASTATIN CALCIUM 469 450 4 9
METFORMIN HCL 435 401 5 8
LOSARTAN POTASSIUM 351 329 6 18
FUROSEMIDE 313 295 7 6
LEVOTHYROXINE SODIUM 307 291 8 1
PRAVASTATIN SODIUM 288 263 9 12
ALENDRONATE SODIUM 258 258 10 23
DILTIAZEM ER 242 237 11 182
OMEPRAZOLE 236 207 12 7
METOPROLOL TARTRATE 228 224 13 10
METOPROLOL SUCCINATE 226 212 14 11
LISINOPRIL-HYDROCHLOROTHIAZIDE 216 206 15 28
WARFARIN SODIUM 194 194 16 22
ATENOLOL 171 165 17 25
LOVASTATIN 157 157 18 41
LANTUS SOLOSTAR 157 117 18 92
LOSARTAN-HYDROCHLOROTHIAZIDE 155 132 20 46
TAMSULOSIN HCL 147 147 21 29
POTASSIUM CHLORIDE 140 135 22 14
METFORMIN HCL ER 140 123 22 53
ALLOPURINOL 139 139 24 37
PANTOPRAZOLE SODIUM 138 138 25 33
CLOPIDOGREL 117 113 26 30
SYNTHROID 117 97 26 52
JANUVIA 110 110 28 48
CIPROFLOXACIN HCL 110 104 28 47
ISOSORBIDE MONONITRATE ER 108 108 30 51
TRIAMTERENE-HCTZ 104 102 31 63
TRAMADOL HCL 102 98 32 16
MELOXICAM 98 90 33 31
CARVEDILOL 97 86 34 21
FLUTICASONE PROPIONATE 93 84 35 32
QUINAPRIL HCL 91 88 36 179
PLAVIX 83 83 37 40
DILTIAZEM 24HR ER 83 83 37 264
PEN NEEDLE 75 62 39 110
HYDROCHLOROTHIAZIDE 74 57 40 15
HYDRALAZINE HCL 70 60 41 59
FINASTERIDE 68 68 42 102
LIPITOR 68 59 42 78
DONEPEZIL HCL 67 67 44 26
ENALAPRIL MALEATE 63 50 45 49
VERAPAMIL ER 60 57 46 104
DIOVAN HCT 56 56 47 61
VENTOLIN HFA 52 40 48 173
CLONIDINE HCL 52 48 48 39
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 4, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.